Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
PainReform ( (PRFX) ) has shared an announcement.
On January 15, 2026, PainReform Ltd. announced it had changed its corporate name to PRF Technologies Ltd., following shareholder approval at the company’s January 6, 2026 annual general meeting, in a move designed to signal its evolution beyond a single-asset pain-treatment developer into a diversified healthcare and clean-energy technology platform. The rebranding highlights the company’s broadened portfolio, which now includes LayerBio’s OcuRing-K sustained-release ocular therapy for post-cataract surgery care and the DeepSolar AI-based solar analytics and forecasting business, positioning PRF to pursue multiple growth paths and reduce reliance on any single product as it targets large, high-growth markets in both specialty pharmaceuticals and renewable energy.
The most recent analyst rating on (PRFX) stock is a Sell with a $0.78 price target. To see the full list of analyst forecasts on PainReform stock, see the PRFX Stock Forecast page.
Spark’s Take on PRFX Stock
According to Spark, TipRanks’ AI Analyst, PRFX is a Neutral.
The score is driven primarily by very weak financial performance (minimal revenue, widening losses, and worsening cash burn with a shrinking equity cushion). Technicals also weigh on the score due to a clear downtrend versus key moving averages, partially offset by oversold indicators. Valuation contributes little support given negative earnings and no dividend yield.
To see Spark’s full report on PRFX stock, click here.
More about PainReform
PRF Technologies Ltd. (formerly PainReform) is a Tel Aviv-based diversified innovation company listed on Nasdaq under the ticker PRFX, operating across specialty pharmaceuticals and AI-driven energy analytics. Its healthcare activities focus on reformulated, sustained-release, non-opioid drug-delivery technologies, including the postoperative pain therapy PRF-110 and ophthalmic products via majority-owned LayerBio, while its DeepSolar platform develops artificial intelligence tools to monitor, forecast and optimize performance of utility-scale solar assets in the renewable-energy sector.
Average Trading Volume: 322,383
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.24M
For a thorough assessment of PRFX stock, go to TipRanks’ Stock Analysis page.